A Study of PEG-EPO Injection (CHO Cells) for Maintenance Therapy of Patients With Renal Anemia .

Renal Anemia Clinical Trial

Official title:

A Phase Ⅱ Clinical Study on the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Polyethylene Glycol Recombinant Human Erythropoietin Injection (CHO Cell) in Optimal Dose and Administration Regimen for Maintenance Therapy in Patients With Regular Dialysis Renal Anemia.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05629598
• Other study ID #: CRAD-006-02
• Status: Recruiting
• Phase: Phase 2
• Start date: April 13, 2022
• Est. completion date: August 16, 2023

Study information

• Verified date: November 2022
• Source: Angde Biotech Pharmaceutical Co., Ltd.
• Contact: Jianghua Chen, Master
• Phone: 0571-87236996
• Email: zyct79[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to explore the optimal dose and administration of the experimental drug, and to evaluate the safety and efficacy of the drug in patients with renal anemia. Patients with renal anemia on regular dialysis treatment are expected to be enrolled in this study.

Description:

This study is a multi-center, randomized, open-label, positive controlled phase II clinical study. A total of 125 to 150 patients with renal anemia receiving regular dialysis were enrolled in this study. Those patients were randomly allocated to 5 treatment groups in a ratio of 1:1:1:1:1, with 25 to 30 patients in each group.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: August 16, 2023
• Est. primary completion date: March 17, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Male and female patients at the age of 18~75 (including critical value).

2. Patients clinically diagnosed with renal anemia who have received dialysis for at least 12 weeks (hemodialysis=3 times/week, total urea clearance index (Kt/V) =1.2 or urea reduction rate (URR) =65%; peritoneal dialysis=4 times/day, weekly Kt/V=1.7);

3. Hb in screening period should be within the range of 100~130g/L (including both ends), and the deviation should not exceed 10g/L;

4. Iron status (TSAT =20% or SF ferritin =100µg/L) during screening.

5. Have been stably treated with short-acting EPO 1-3 times per week for at least 12 weeks before baseline;

6. Consent to use reliable contraceptive methods and no family planning from the screening period to 3 months after the last administration;

7. Voluntarily participate in the trial and sign the informed consent form.

Exclusion Criteria:

1. Patients with a history of severe allergies (including drug allergies), especially allergic to erythropoietin, or to any component of the test drug (e.g. polyethylene glycol);

2. Have a history of kidney transplantation or plan to undergo kidney transplantation during the trial;

3. Have any other disease that causes chronic anemia (e.g., sickle cell anemia, myelodysplastic syndrome, hematologic malignancy, myeloma, hemolytic anemia, pure red cell aplastic anemia) or PRCA following therapy of erythropoietin protein;

4. Suffered from acute or chronic blood loss (such as gastrointestinal bleeding) or undergwent surgical procedures due to massive bleeding within 3 months before screening, or plan to have a surgery during the clinical trial (except for arteriovenous fistula or peritoneal dialysis tube adjustment);

5. Have a history of malignant tumors within the past 5 years (excluding non-melanoma skin cancer or excised carcinoma in situ);

6. Suffer from autoimmune diseases (such as rheumatoid arthritis or systemic lupus erythematosus) or diseases of endocrine system (such as poorly controlled diabetes mellitus complicated with peripheral vascular diseases, severe secondary hyperparathyroidism [parathyroid hormone > 800ng/L]);

7. Received systemic antibiotic treatment or C-reactive protein =30mg/L within 4 weeks due to severe infection before screening;

8. The following conditions occur during screening period:

Hepatic dysfunction (AST or ALT>3 times ULN); Coagulation dysfunction (activated partial thrombin time > 1.5 times ULN); Folic acid or vitamin B12 deficiency (serum folic acid level <LLN, vitamin B12 <LLN); Positive for HBsAg, HBcAb, HIV-ABb, HCV-AbB or TP-Ab;

9. Suffer from severe thromboembolic disease, poorly controlled severe hypertension (SBP before dialysis > 170mmHg or DBP =100mmHg) or hypotension (SBP before dialysis <90mmHg);

10. Suffer from severe cardiovascular and cerebrovascular disease, severe or unstable coronary artery disease, heart failure (NYHA CLASS III or IV), or those who received coronary artery bypass grafting or percutaneous coronary intervention within 6 months, or those who had a history of myocardial infarction or stroke within 3 months;

11. Received androgen therapy or blood transfusion within 8 weeks before screening period;

12. Received long-acting ESAs within 3 months or HIF-PHI (e.g., rosalat) within 2 weeks before initial administration;

13. Participated in other clinical trials as a subject within 4 weeks before screening period or the duration from the last administration to enrollment was shorter than the 5 half-lives of the drug;

14. Have a history of epileptic seizures or mental illness;

15. Alcoholism, drug abuse or drug addiction

16. Pregnant or breastfeeding;

17. Investigator considers not suitable to enter this trial.

Related Conditions & MeSH terms

• Anemia
• Renal Anemia

Intervention

Biological:
• Recombinant human erythropoietin injection
The dose of PEG-EPO (CHO cells) is converted according to the average weekly dose of short-acting EPO before randomization (4 weeks before randomization) multiplied by the corresponding conversion coefficient (low conversion coefficient is 0.004, High conversion coefficient is 0.008).
• Human erythropoietin injection
Refer to the product instructions

Locations

Country	Name	City	State
China	The First Affiliated Hospitial,College of Medicine,Zhejiang University	Hanzhou	Zhejiang

Sponsors (1)

Lead Sponsor	Collaborator
Angde Biotech Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change of mean hemoglobin compared to baseline during fixed treatment	Change of mean hemoglobin (Hb) content from baseline during fixed treatment (fixed treatment:week 1 to week 6)	Day1-Day42
Primary	Change of mean hemoglobin during dose adjustment period	Change of mean hemoglobin compared to baseline from week 13 to 18 during dose adjustment period (dose adjustment period: week 7 to week 18/week 20).	Day85-Day126
Secondary	Proportion of patients with hemoglobin keeping within the target range	Proportion of patients with hemoglobin keeping within the target range (target range: the variation from baseline Hb is within ±10g/L, and HB is in the range of 100-130g/L) during treatment period (fixed treatment, week 13 to 18 during dose adjustment period).	Day1-Day42?Day85-Day126
Secondary	Reticulocyte count, Hematocrit, Erythrocyte count	Changes of mean values of other evaluation indexes (including HCT, RET, RBC) between baseline and different stages of treatment (fixed treatment period, week 13 to 18 of dose adjustment period).	Day1-Day42?Day85-Day126
Secondary	Proportion of patients receiving red blood cell transfusion and number of transfusions during the trial.		Day1-Day126/140
Secondary	Number of iron deficiency, number of patients and proportion of patients with iron deficiency during the trial	Iron deficiency was defined as SF=100µg/L and TSAT=20% in peritoneal dialysis subjects; SF=200µg/L and TSAT=20% in hemodialysis subjects.	Day1-Day126/140
Secondary	The number and proportion of patients with dose adjustments during the trial		Day1-Day126/140
Secondary	Anti-drug antibody	The incidence of ADA and Nab	1,5, 9, 13, 17 weeks (before administration) and 28±2 days after the last administration (A2/B2group ,A1/B1 patients with intensive blood collection) or 14±2 days after the last administration (A1/B1 patients with sparse blood collection)
Secondary	Adverse events	Any adverse event that occurred during the clinical trials of all patients.	Day1-Day126/140
Secondary	Cmax	Maximum observed plasma concentration of EPO.	Day1-Day126/140
Secondary	Tmax	Time to maximum observed plasma concentration of EPO.	Day1-Day126/140
Secondary	AUC 0-t	Area under the plasma concentration-time curve from time 0 to the time of the last measurable concentration of EPO.	Day1-Day126/140
Secondary	AUC 0-8	Area under the plasma concentration-time curve from time 0 to infinity.	Day1-Day126/140
Secondary	Emax	Maximal effect concentriation	Day1-Day126/140
Secondary	Tmax of Emax	Time to maximal effect concentriation	Day1-Day126/140
Secondary	AUE0-t	Area under the plasma effect-concentriation curve from time 0 to the time of the last measurable concentration of EPO.	Day1-Day126/140